Publication | Closed Access

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

Linc 3Withdrawal PhaseMedicineClinical TrialsPharmacotherapyAdrenal DiseaseEndocrinologyPharmacologyEndocrine Disease